[HTML][HTML] Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial

…, M Zaidan, CLT Le Tiec, CV Verstuyft… - JAMA internal …, 2021 - jamanetwork.com
… estimates of probability of (A) the primary outcome, death or ventilation support (mechanical
ventilation, high-flow or noninvasive ventilation); B, death or mechanical ventilation; (C) …

[HTML][HTML] Genetic determinants of response to clopidogrel and cardiovascular events

T Simon, C Verstuyft, M Mary-Krause… - New England journal …, 2009 - Mass Medical Soc
Background Pharmacogenetic determinants of the response of patients to clopidogrel
contribute to variability in the biologic antiplatelet activity of the drug. The effect of these …

Dihydropyrimidine dehydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: update and recommendations of the French …

…, N Picard, L Becquemont, C Verstuyft, C Narjoz… - Bulletin du …, 2018 - europepmc.org
Fluoropyrimidines (FU) are still the most prescribed anticancer drugs for the treatment of solid
cancers. However, fluoropyrimidines cause severe toxicities in 10 to 40% of patients and …

PPAR-γ agonists for the treatment of major depression: a review

…, S Rotenberg, F Hozer, P Hardy, C Verstuyft… - …, 2017 - thieme-connect.com
Introduction: Selective agonists of the nuclear transcription factor peroxisome proliferator-activated
receptor-gamma (PPAR-γ) are used for the treatment of type 2 diabetes. We reviewed …

Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity

L Bodin, C Verstuyft, DA Tregouet, A Robert, L Dubert… - Blood, 2005 - ashpublications.org
The aim of the study is to explore the contribution of genetic factors related either to drug
metabolism (cytochrome P450 2C9) or to drug target (vitamin K epoxide reductase) to variability …

Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial

…, M Zaidan, CLT Le Tiec, CV Verstuyft… - The Lancet …, 2021 - thelancet.com
Background Patients with COVID-19 pneumonia have an excess of inflammation and
increased concentrations of cytokines including interleukin-1 (IL-1). We aimed to determine …

Major Depressive Disorder and Oxidative Stress: A Review of Peripheral and Genetic Biomarkers According to Clinical Characteristics and Disease Stages

…, K Chappell, J Bouligand, L Becquemont, C Verstuyft - Antioxidants, 2023 - mdpi.com
… Ascorbic acid, also known as vitamin C, is a critical molecule for various biological pathways
from collagen synthesis to neuroprotection [22,101]. Even if its mechanisms remain partially …

Environmental and genetic factors associated with morphine response in the postoperative period

L Coulbault, M Beaussier, C Verstuyft… - Clinical …, 2006 - Wiley Online Library
… The PCR program was started with 2 minutes at 50C and then 10 minutes at 95C,
followed by 35 cycles consisting of 92C for 15 seconds and 60C for 1 minute. The post-PCR–…

Digoxin pharmacokinetics and MDR1 genetic polymorphisms

C Verstuyft, M Schwab, E Schaeffeler, R Kerb… - European journal of …, 2003 - Springer
… 893 (C→T transition leading Ala→Ser and C→A transition leading to Ala→Thr) [3]. Moreover,
the results from Hoffmeyer et al. [2] were obtained in an heterogeneous group of healthy …

Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial …

…, E Drouet, G Mulak, V Bataille, J Ferrières, C Verstuyft… - Circulation, 2011 - Am Heart Assoc
Background— Clopidogrel requires metabolic activation by cytochrome P450 2C19 (CYP2C19).
Proton pump inhibitors (PPIs) that inhibit CYP2C19 are commonly coadministered with …